Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A retrospective, multicenter, observational study analysing effect of disease modifying therapies on Covid-19 severity in patients with multiple sclerosis

Next Previous
Trial Profile

A retrospective, multicenter, observational study analysing effect of disease modifying therapies on Covid-19 severity in patients with multiple sclerosis

Status: Recruiting
Phase of Trial: Phase IV

Latest Information Update: 10 Jun 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ocrelizumab (Primary) ; Rituximab (Primary) ; Anti CD20 antibody; Interferon
  • Indications Multiple sclerosis
  • Focus Adverse reactions

Most Recent Events

  • 10 Jun 2021 New trial record
  • 22 Apr 2021 Results (on October 12; n=902) presented at the 73rd Annual Meeting of the American Academy of Neurology

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top